Search results
FDA Approves Geron's First Commercial Drug, Competes With Bristol Myers Squibb's Blood Cancer Drug
Benzinga via Yahoo Finance UK· 4 weeks agoOn Thursday, the FDA approved Geron Corporation's (NASDAQ:GERN) Rytelo (imetelstat) for adult...
Zoe Ball's son Woody's emotional tribute to 'wonderful granny' after her death
OK! Magazine via Yahoo News· 2 months agoWoody Cook has made a heartfelt tribute to his 'wonderful' grandma Julia, saying goodbye to her...
Zoe Ball heartbroken as she announces the death of her mother after tragic cancer diagnosis
Daily Record via Yahoo News UK· 2 months agoZoe Ball shared the sad news of her mother's death on social media in the early hours of this...
Zoe Ball supported as she announces mum's death just weeks after sharing cancer diagnosis
Manchester Evening News via Yahoo News UK· 2 months agoZoe Ball -Credit:BBC/Ray Burmiston Zoe Ball has been flooded with messages of condolence after she...
Zoe Ball announces death of her mum after cancer battle
OK! Magazine via Yahoo News· 2 months agoZoe Ball has announced on her social media this morning (Tuesday, 24 April) that her mum Julia...
Zoe Ball gives emotional update on mum's devastating cancer battle
OK! Magazine via Yahoo News· 2 months agoZoe Ball has shared an emotional update on her mother Julia's cancer battle, revealing that she has...
Geron Corporation (NASDAQ:GERN) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance UK· 2 months agoGeron Corporation (NASDAQ:GERN) Q1 2024 Earnings Call Transcript May 2, 2024 Geron Corporation beats...
Geron Corp (GERN) Q1 2024 Earnings Call Transcript Highlights: Strategic Moves and Financial Health
GuruFocus.com via Yahoo Finance UK· 2 months agoCash and Marketable Securities: Approximately $465 million as of March 31, 2024. Net Proceeds from Public Offering: Approximately $141 million in March 2024. Total Operating Expenses Q1 2024 ...
UPDATE 3-US FDA staff raises concerns on Geron's blood disorder drug
Reuters via Yahoo Finance UK· 4 months agoThe U.S. Food and Drug Administration's staff reviewers said on Tuesday they were unclear if Geron's blood disorder drug provided a clear benefit to patients in a late-stage trial and raised ...